THOR CEO leads official US Congressional Briefing on Photobiomodulation (PBM)

Washington DC, 11th October, 2018. James Carroll (CEO, THOR Photomedicine), Prof. Praveen Arany (University at Buffalo, NY), Annette Quinn RN (Program Manager, Radiation Oncology, University of Pittsburgh (UPMC) Cancer Center) introduced Photobiomodulation (PBM) to a large gathering of senior policy officials at the Rayburn House Office Building.

James Carroll presented evidence to Congress on the effectiveness of PBM for treating pain and where it can be used in place of opioids. Prof. Praveen Arany explained how and why it works, and Annette Quinn RN gave her first hand experience in treating over 854 patients with Oral Mucositis.

The briefing was a historic step for PBM, moving the conversation forward as members of congress were shown stories by members of the public on how PBM had impacted them and enabled them to live a life free from opioids.

The panel outlined the needs for PBM adoption as

  1. Research grants to fund further basic science experiments, therapeutic dose, and large multicenter clinical trials.
  2. FDA to create a PBM specific product code.
  3. Public and private health insurance reimbursement.

For further information on this event visit

This entry was posted in Industry, THE FUTURE OF PBM/LLLT. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *